Iberiotoxin TFA(IbTX) is a toxin purified from the scorpion Buthus tamulus. Iberiotoxin is a potent blocker of the large conductance Ca(2+)-activated K+ channel with a Kd of ~1 nM.

REGN5678 is a bispecific antibody targeting both PSMA on prostate cancer cells and CD28 on T-cells to enhance immune activation. It is being developed for the treatment of prostate cancer by redirecting T-cells to PSMA-expressing tumors, promoting tumor cell death. M.W 145.86 kDa

Flotetuzumab is a bispecific DART antibody targeting CD123 on tumor cells and CD3ε on T-cells to stimulate immune cell-mediated tumor lysis. It is being developed for the treatment of hematological malignancies by enhancing T-cell responses against CD123-expressing tumors. M.W 58.91 kDa

M701 is a bispecific antibody targeting CD3 on T-cells and EpCAM on tumor cells to stimulate T-cell-mediated tumor cell death. It is being developed for the treatment of malignant ascites by redirecting T-cells to EpCAM-expressing tumors. M.W 125.84 kDa

Lomvastomig is a bispecific antibody targeting both PD-1 and TIM-3 to inhibit immune checkpoint regulation and enhance immune responses. It is designed to treat cancers by promoting T-cell activation and overcoming immune suppression. M.W 145.34 kDa

Vudalimab is a bispecific antibody targeting PD-1 and CTLA-4 to inhibit immune checkpoint regulation and enhance immune responses. It is being developed for the treatment of advanced malignancies by promoting T-cell activation against tumors and metastatic castration-resistant prostate cancer (mCRPC). M.W 125.43 kDa

Zenocutuzumab is a humanized bispecific IgG1 antibody targeting HER2 and HER3 to enhance antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth. It is being developed for the treatment of cancers overexpressing HER2 and HER3, leveraging dual targeting for enhanced antitumor activity. M. W 145.88 kDa

Vanucizumab is a humanized bispecific IgG1 antibody targeting VEGF-A and Ang-2 to inhibit tumor angiogenesis. It is being developed for the treatment of advanced solid tumors demonstrating anti-tumor, anti-angiogenic, and anti-metastatic effects. M.W 146.89 kDa

Ubamatamab is a bispecific IgG4-based antibody targeting MUC16 on tumor cells and CD3 on T cells to enhance immune activation. It is designed for the treatment of ovarian cancer by recruiting T cells for MUC16-directed tumor cell killing with reduced Fcγ receptor affinity. M.W 144.64 kDa

Nivatrotamab is a humanized bispecific antibody targeting GD2 on tumor cells and CD3 on T cells to enhance immune activation. It is being developed for the treatment of metastatic small cell lung cancer (SCLC) by recruiting T cells to attack tumors. M. W 200.96 kDa